JF
FDMT icon

Jump Financial’s 4D Molecular Therapeutics FDMT Stock Holding History

Jump Financial’s Portfolio FDMT Stock Details FDMT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-33,830
Closed -$254K – 2044
2025
Q4 		$254K Buy
+33,830
New +$343K ﹤0.01% 1633
2025
Q1 		– Sell
-94,689
Closed -$527K – 1717
2024
Q4 		$527K Buy
94,689
+19,196
+25% +$151K 0.01% 1044
2024
Q3 		$816K Buy
75,493
+46,128
+157% +$766K 0.02% 883
2024
Q2 		$616K Buy
29,365
+326
+1% +$8.18K 0.01% 1047
2024
Q1 		$925K Buy
+29,039
New +$741K 0.03% 848
2022
Q3 		– Sell
-22,500
Closed -$157K – 1695
2022
Q2 		$157K Buy
+22,500
New +$219K 0.01% 1358
2022
Q1 		– Sell
-26,593
Closed -$583K – 1655
2021
Q4 		$583K Buy
+26,593
New +$652K 0.04% 587

Other funds holding FDMT

Janus Henderson Group
Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.72B AUM 106.92% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return

Jump Financial's FDMT Position: Q1 2026 in Review

Jump Financial sold out of 4D Molecular Therapeutics (FDMT) in Q1 2026, closing a stake of 33,830 shares — an estimated $254K sold.

Jump Financial first reported a position in FDMT in Q4 2021 and held it in 7 quarters. The position peaked at $925K in Q1 2024. 153 funds tracked by Wall St. Rank hold FDMT as of Q1 2026.

  • Jump Financial reported no remaining 4D Molecular Therapeutics position as of Q1 2026 after selling out during the quarter.
  • Jump Financial sold 33,830 4D Molecular Therapeutics shares in Q1 2026, an estimated $254K.
  • Jump Financial first reported a position in 4D Molecular Therapeutics in Q4 2021 and held it in 7 quarters.
  • Jump Financial's 4D Molecular Therapeutics position peaked at $925K in Q1 2024.
  • 153 funds tracked by Wall St. Rank held 4D Molecular Therapeutics as of Q1 2026.

Based on Jump Financial's 13F filing for Q1 2026, filed 14 May 2026.